Startup profile · funding coverage
Neurosterix funding, valuation and investors
Clinical-stage neuropsychiatry developer designing selective brain-receptor modulators, led by investigational oral M4 programme NTX-253 for schizophrenia.
Verified company research · funding, investors and latest developments
Keep track of Neurosterix
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series B
$105M · November 12, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$168M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series b · Boston, Massachusetts, US; Geneva, Switzerland
Investors in latest funding
Lead: RTW Investments
Other: Janus Henderson Investors , GV , Ikarian Capital , Affinity Asset Advisors , Dellora Investments , Perceptive Advisors , Acorn Bioventures
Overview
Neurosterix operates from Boston and Geneva and develops selective allosteric modulators: small molecules that change receptor activity by binding outside the receptor's primary active site. Its oral M4-positive allosteric modulator NTX-253 aims to treat schizophrenia; the company reported completed Phase 1 single- and multiple-dose studies supportive of further trials, with Phase 2 planned.
NTX-819 targets mGlu7 and is preclinical, while NTX-529 is another M4 programme. The company's technology originated in a 2024 transaction involving Addex Therapeutics. $105M Series B announced November 12, 2026 led by RTW Investments, on top of a separate $63M Series A announced April 3, 2024. The investor page calls cumulative funding about $170M (rounded); the two separately quantified rounds sum to $168M.
Why Neurosterix is interesting
Announced a $105M RTW-led Series B on November 12, 2026 after a $63M April 2024 Series A. Its Phase 1 NTX-253 study has completed and Phase 2 remains planned. The muscarinic mechanism has clinical precedent, but Neurosterix's candidate has not demonstrated Phase 2 efficacy or gained approval.
Product & use cases
NTX-253 is an investigational brain-penetrant, orally dosed positive allosteric modulator of the muscarinic M4 receptor. Researchers optimize compound selectivity in receptor assays and preclinical models, evaluate safety and drug exposure in humans (completed Phase 1 according to the company), then plan to test efficacy and tolerability in patients with schizophrenia in Phase 2. No approved product, therapeutic pricing, customer revenue or demonstrated clinical benefit has been disclosed.
- Research and development of NTX-253 as an investigational oral schizophrenia therapy, contingent on Phase 2/3 efficacy and safety.
- Preclinical screening of mGlu7 negative allosteric modulators targeting mood and anxiety conditions.
- Discovery of selective muscarinic receptor medicines, including NTX-529 for additional psychosis and mood indications.
Key facts
- $105M Series B led by RTW Investments, announced Nov 12, 2026; $63M Series A in April 2024 led by Perceptive Xontogeny Venture Fund II.
- The company describes total financing as approximately $170M, while $63M + $105M = $168M across the two separately announced rounds.
- Completed Phase 1 trials are not proof of efficacy in people with schizophrenia; Phase 2 is planned, not completed.
- NTX-253 is a selective muscarinic M4 positive allosteric modulator; NTX-819 and NTX-529 are separate development programmes.
- Addex contributed the originating small-molecule discovery platform and other assets in 2024; no 2026 IPO or acquisition has been announced.
Funding history (newest first)
Series B
2026-11-12 $105M- RTW Investments (lead)
- Janus Henderson Investors (participant)
- GV (participant)
- Ikarian Capital (participant)
- Affinity Asset Advisors (participant)
- Dellora Investments (participant)
- Perceptive Advisors (participant)
- Acorn Bioventures (participant)
Source: Read source · businesswire.com
Series A
2024-04-03 $63M- Perceptive Xontogeny Venture Fund II (lead)
- Perceptive Life Sciences Fund (participant)
- Acorn Bioventures (participant)
Source: Read source · businesswire.com
Competitive landscape
Edge: Selective M4 allosteric modulation may offer a differentiated mechanism and dosing profile relative to dopamine-targeted antipsychotics or already-approved muscarinic approaches. Neurosterix's clinical advantage remains a hypothesis; the company has not disclosed controlled clinical efficacy in patients.
-
Bristol Myers Squibb (COBENFY) alternative
Approved muscarinic-based schizophrenia treatment with a different pharmacological profile; approval does not validate NTX-253 efficacy.
-
Karuna Therapeutics adjacent
Historical developer of KarXT, acquired by BMS; the founder experience of new Neurosterix executives is not evidence of clinical success.
-
Existing dopamine-receptor antipsychotics incumbent
Established generic and branded treatment class, with known benefit-risk profiles; comparison needs controlled trials.
-
Other investigational M4 positive allosteric modulators direct
Clinical-stage rival approaches may differ in receptor selectivity, exposure, and efficacy; cross-trial comparisons are unreliable.
Market / IPO context
Editorial / static context — not a live quote.
FAQs about Neurosterix
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.